Migraine is known to be one of the three most prevalent diseases in the world and the disease is prevalent in around 14% of the entire world population. In the US, the prevalence of Migraine is around 12% of the US population.
The report gives the overview of Migraine disease indication in detail and highlights the Migraine epidemiology split into Episodic and Chronic Migraine in the present scenario and in future (forecasted) as well in the key geographies across the globe.
The report starts with the basic definition, causes and symptoms of Migraine and further details the types of Migraine disease indication. The report covers further details on the profile of an Migraine patient, Symptoms of Migraine patient, and disease progression in a Migraine patient. The report further highlights the multiple methods through which the patient can be diagnosed for Migraine.
The later part of the report consists of Migraine epidemiology and prevalence split into Episodic and Chrnoci Migraine in the key geographies across the globe like US, UK, Germany, Italy, France, Spain, Japan etc. The epidemiology for Migraine indication across key geographies has been forecasted till 2024 as well in the report.
Key Topics Covered:
- Migraine Definition
- Classification of Migraine based on symptoms and severity and based on frequency of attacks
- Causes of Migraine
- Profile of Migraine patient
- Symptoms of Migraine patient
- Disease progression and impact on QoL
- Disease diagnosis
- Disease Epidemiology in key markets including Episodic and Chronic Migraine split
- Eli Lilly
- Glaxo Smithkline
- Briston Mayers
- Allodynic Therapeutics
- Pharmalyte Solutions
- Ionis Pharmaceuticals
- Helsinn Group
- Otsuka Holdings
- NeurAxon Inc.
- Achelios Thera
For more information about this report visit https://www.researchandmarkets.com/research/932n6g/2018_migraine?w=4